Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | QPCT | Q16769 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30731669 | 1.00 | LMNA (0.39) | LMNAMAPTQPCTALDH1A1MEN1 | |
| SCHEMBL30977369 | 0.88 | L3MBTL1 (0.38) | MAPTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL24525268 | 0.84 | APLNR (0.41) | LMNAMAPTQPCTALDH1A1MEN1 | |
| SCHEMBL29654693 | 0.84 | APLNR (0.41) | LMNAMAPTQPCTALDH1A1MEN1 | |
| SCHEMBL27038894 | 0.83 | LMNA (0.39) | LMNAMAPTQPCTALDH1A1MEN1 | |
| SCHEMBL27051834 | 0.83 | QPCT (0.40) | LMNAMAPTQPCTALDH1A1MEN1 | |
| SCHEMBL30727410 | 0.83 | LMNA (0.39) | LMNAMAPTQPCTALDH1A1MEN1 | |
| SCHEMBL30727443 | 0.82 | ALDH1A1 (0.39) | LMNAMAPTQPCTALDH1A1MEN1 | |
| SCHEMBL27038917 | 0.82 | ALDH1A1 (0.39) | LMNAMAPTQPCTALDH1A1MEN1 | |
| SCHEMBL27038907 | 0.81 | QPCT (0.38) | LMNAMAPTQPCTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4558498-A1 | NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| EP-4558479-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024017858-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024017857-A1 | NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024017858-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | CBR3, HAX1, CBR1 | LMNA 1245/4885MAPT 4870/4885QPCT 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.